Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 12400 High Bluff Drive SAN DIEGO CA 92130 |
Tel: | N/A |
Website: | https://www.tandemdiabetes.com |
IR: | See website |
Key People | ||
Leigh A. Vosseller Chief Financial Officer, Executive Vice President, Treasurer | David B. Berger Chief Operating Officer, Executive Vice President | Susan M. Morrison Executive Vice President, Chief Administrative Officer |
Elizabeth A. Gasser Executive Vice President, Chief Strategy Officer | Brian B. Hansen Chief Commercial Officer, Executive Vice President | Shannon M. Hansen Senior Vice President, Chief Compliance Officer, General Counsel, Chief Privacy Officer and Secretary |
James A. Leal Senior Vice President - Operations | Rick Carpenter Chief Technical Officer |
Business Overview |
Tandem Diabetes Care, Inc. is a medical device company. The Company is focused on the design, development, and commercialization of technology solutions for people living with diabetes. It manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. Its manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on the Company's technology platform and is the smallest durable insulin pump available in the United States. The Company has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range. It was cleared by the Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar. |
Financial Overview |
For the three months ended 31 March 2023, Tandem Diabetes Care Inc revenues decreased 4% to $169.4M. Net loss increased from $14.7M to $123.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other Selling, general and administ. increase of 23% to $75.7M (expense), Research and development - Balancing val increase of 28% to $36.7M (expense). |
Employees: | 2,600 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1,365M as of Mar 31, 2023 |
Annual revenue (TTM): | $794.69M as of Mar 31, 2023 |
EBITDA (TTM): | -$191.23M as of Mar 31, 2023 |
Net annual income (TTM): | -$203.75M as of Mar 31, 2023 |
Free cash flow (TTM): | -$30.80M as of Mar 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 64,621,839 as of Apr 28, 2023 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |